Health Care & Life Sciences » Pharmaceuticals | Relmada Therapeutics Inc.

Relmada Therapeutics Inc. | Income Statement

Fiscal year is July-June. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
0.40
2.30
9.30
54.80
85.30
2.60
Gross Income
0.40
2.30
9.30
54.80
85.30
2.60
SG&A Expense
6,773.60
12,944.50
17,090.00
16,160.80
7,133.60
6,914.80
EBIT
6,773.90
12,946.80
17,099.30
16,215.60
7,218.80
6,917.50
Unusual Expense
12,877.70
7,955.00
3,710.30
13,108.90
818.20
708.90
Non Operating Income/Expense
-
-
-
130.30
114.60
2.40
Interest Expense
220.30
435.60
4.90
-
0.60
1,336.80
Pretax Income
19,871.90
21,336.00
20,803.60
2,974.70
6,286.50
8,960.90
Consolidated Net Income
19,871.90
21,336.00
20,803.60
2,974.70
6,286.50
8,960.90
Net Income
19,871.90
21,336.00
20,803.60
2,974.70
6,286.50
8,960.90
Net Income After Extraordinaries
19,871.90
21,336.00
20,803.60
2,974.70
6,286.50
8,960.90
Net Income Available to Common
19,871.90
21,336.00
20,803.60
2,974.70
6,286.50
8,960.90
EPS (Basic)
1.58
1.69
2.09
0.26
0.52
0.71
Basic Shares Outstanding
12,596.50
12,596.50
9,941.20
11,599.00
12,074.20
12,545.30
EPS (Diluted)
1.58
1.69
2.09
0.26
0.52
0.71
Diluted Shares Outstanding
12,596.50
12,596.50
9,941.20
11,599.00
12,074.20
12,545.30
EBITDA
6,773.60
12,944.50
17,090.00
16,160.80
7,133.60
6,914.90
Non-Operating Interest Income
-
1.40
10.90
1.70
-
-

About Relmada Therapeutics

View Profile
Address
880 Third Avenue
New York New York 10022
United States
Employees -
Website http://www.relmada.com
Updated 07/08/2019
Relmada Therapeutics, Inc. is a clinical-stage and biotechnology company, which engages in developing drug products together with new chemical entities that address areas of unmet medical need in the treatment of central nervous system diseases. Its portfolio of products include d-Methadone, LevoCap ER, BuTab REL-1028, and MepiGel REL-1021. The company was founded on May 31, 2012 and is headquartered in New York, NY.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.